Kent Nybakken

Kent Nybakken has a diverse work experience spanning over 30 years. From 1990 to 2000, they worked as a Research Associate at Xoma Corporation, where they developed and ran ELISA, HPLC, and electrophoretic assays for quality control of therapeutic immunoglobulins targeting sepsis. Kent also entered, verified, and vetted patient clinical data for therapeutic immunoglobulins. From 2000 to 2007, they worked as a Scientist at Harvard Medical School, where they conducted research focused on genome-wide screening to elucidate cell signaling pathways. Kent used high-throughput RNA interference screening and functional genomics to identify new components of the Hedgehog (Hh) signaling pathway. From 2007 to 2015, they worked as a Scientist at Aquinnah Pharmaceuticals, where they created cell lines used in stress granule assays and increased throughput of HTS assay designed to identify small molecules preventing the formation and persistence of stress granules for lead series development of ALS therapeutics. From 2015 to 2016, they were a Substitute Teacher at Bedford Public Schools. From 2016 to 2018, they were a Sales Associate at REI. From 2019 to 2020, they were an Associate Study Director at Toxikon, where they were responsible for the technical conduct of in vitro cell studies and the documentation, analysis, and reporting of study results. Currently, they are a Scientist II at Marengo Therapeutics.

Kent Nybakken received a B.A. in Zoology from the University of California, Berkeley and a Doctor of Philosophy (Ph.D.) in Biochemistry from the University of California, San Francisco.